Metabolic Medicine

High-Dose Thiamine Treatment

At a Glance

High-dose oral thiamine is the lifelong standard treatment for TRMA. It usually corrects megaloblastic anemia and may improve blood sugar control, but it does not reliably restore established hearing or vision problems, so specialist monitoring remains important.

The discovery that high doses of thiamine (Vitamin B1) can treat this condition was a breakthrough in rare disease care ^[1]. While thiamine is a vitamin found in food, the amounts needed for TRMA are “pharmacologic”—meaning they are much higher than what you would get from a balanced diet or a standard multivitamin ^[1]^[2].

The Standard of Care

The primary treatment for TRMA is lifelong oral thiamine ^[1]. Because the body’s usual “doorways” for thiamine are broken, giving very high doses allows the vitamin to bypass those doorways via lower-affinity pathways and reach the cells that need it ^[3].

Dose Range: Published dosing varies depending on age, formulation, and clinical response, though doctors typically prescribe between 25 mg and 200 mg per day ^[3]^[2]. Some children may start on lower doses that are gradually increased based on how their blood counts and blood sugar respond ^[4]^[5]. Research involving groups of patients has shown that doses above 150 mg per day generally do not provide additional benefits for most people, but there is no universal patient-directed maximum ^[3].
Do Not Self-Adjust: It is critical that caregivers never start, stop, double, or reduce a thiamine dose without strict supervision from the prescribing team. Your specialist will customize the exact dose based on lab results.
Lifelong Commitment: It is critical to understand that thiamine is not a “cure” that can be stopped once symptoms improve. If treatment is interrupted—even for a few weeks—the anemia and high blood sugar can quickly return ^[6]^[7].

What Thiamine Can Improve

For most children, thiamine treatment has a dramatic and positive impact on two of the three main symptoms of TRMA:

Correcting Anemia: High-dose thiamine is highly effective at fixing the megaloblastic anemia ^[3]. Within weeks to months of starting treatment, the bone marrow begins to produce healthy, normal-sized red blood cells ^[5]. Most patients achieve transfusion independence, meaning they no longer need blood transfusions to stay healthy ^[3]^[8].
Managing Diabetes: Thiamine helps the pancreas function more effectively. While it does not always eliminate the need for insulin, it often improves glycemic control (blood sugar levels) and allows many children to reduce their daily insulin doses ^[3]. In some cases, children have been able to stop taking insulin entirely, though this must only be done under strict medical supervision due to the risk of dangerous hypoglycemia (low blood sugar) as insulin needs fall ^[3]^[9].

Limitations of Treatment

While thiamine is a powerful tool, it has limits. It is most effective when started as early as possible, but it cannot fix everything:

Hearing Loss: Thiamine generally does not reverse hearing loss once it has occurred ^[10]^[11]. Even with early and consistent thiamine treatment, some children may still experience a slow decline in their hearing over time ^[10]^[12].
Vision Changes: Evidence is mixed regarding the eyes. Some reports suggest early thiamine might help protect the retina, but it has not been shown to reverse established vision issues like retinitis pigmentosa or optic atrophy ^[11]^[13]^[14].

Because TRMA affects multiple systems, your child’s treatment plan should be managed by a team that includes a metabolic specialist or geneticist, working alongside hematologists and endocrinologists to ensure all aspects of the condition are monitored ^[15]^[16].

Common questions in this guide

What dose of thiamine is commonly used for TRMA?

Doctors often prescribe 25 to 200 mg of oral thiamine per day for TRMA, depending on age, formulation, laboratory results, and clinical response. The exact dose must be set and changed only by the prescribing team.

Does thiamine need to be taken for life in TRMA?

Yes. Thiamine is not a cure that can be stopped when symptoms improve; interrupting treatment for even a few weeks can allow anemia and high blood sugar to return.

How does high-dose thiamine affect anemia and diabetes in TRMA?

It usually corrects megaloblastic anemia within weeks to months, and many patients no longer need transfusions. It often improves blood sugar control and may lower or sometimes eliminate insulin needs, but insulin changes require close medical supervision.

Will thiamine restore hearing or vision problems caused by TRMA?

Thiamine generally does not reverse hearing loss once it has occurred. Evidence for protecting vision is mixed, and established retinitis pigmentosa or optic atrophy is not known to reliably reverse with treatment.

What monitoring is needed during TRMA thiamine treatment?

Care teams usually follow blood counts and blood sugar to tailor thiamine and diabetes treatment. A metabolic specialist or geneticist may coordinate care with hematology and endocrinology, while audiology and eye follow-up monitor hearing and vision.

Can we change the thiamine or insulin dose at home?

No. Do not start, stop, double, or reduce thiamine without guidance from the prescribing team. If insulin needs fall, changes must follow a medical plan because too much insulin can cause dangerously low blood sugar.

Get notified when new evidence is published on Thiamine-responsive megaloblastic anemia syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (16)

1
[Thiamine-responsive megaloblastic anemia or Rogers syndrome: A literature review].
Lu H, Lu H, Vaucher J, et al.
La Revue de medecine interne 2019; (40(1)):20-27 doi:10.1016/j.revmed.2018.06.005.
PMID: 30031565
2
Infantile-onset thiamine responsive megaloblastic anemia syndrome with SLC19A2 mutation: a case report.
Katipoğlu N, Karapinar TH, Demir K, et al.
Archivos argentinos de pediatria 2017; (115(3)):e153-e156 doi:10.5546/aap.2017.eng.e153.
PMID: 28504500
3
Pharmacogenomics in diabetes: outcomes of thiamine therapy in TRMA syndrome.
Habeb AM, Flanagan SE, Zulali MA, et al.
Diabetologia 2018; (61(5)):1027-1036 doi:10.1007/s00125-018-4554-x.
PMID: 29450569
4
Beta cell function and clinical course in three siblings with thiamine-responsive megaloblastic anemia (TRMA) treated with thiamine supplementation.
Potter K, Wu J, Lauzon J, Ho J
Journal of pediatric endocrinology & metabolism : JPEM 2017; (30(2)):241-246.
PMID: 28076318
5
Thiamine-Responsive Megaloblastic Anemia Syndrome Mimicking Myelodysplastic Neoplasm.
Klötzer C, Schnabel F, Kubasch AS, et al.
Acta haematologica 2025; (148(4)):380-385 doi:10.1159/000542286.
PMID: 39467528
6
Pancytopenia in an adult patient with thiamine-responsive megaloblastic anaemia.
Moulin V, Grandoni F, Castioni J, Lu H
BMJ case reports 2018; (2018()) doi:10.1136/bcr-2018-225035.
PMID: 29903777
7
Relapse of rare diseases during COVID-19 pandemic: bicytopenia in an adult patient with thiamine-responsive megaloblastic anaemia.
Nouira N, Mansouri R, Tlili R, et al.
The Pan African medical journal 2020; (35(Suppl 2)):139 doi:10.11604/pamj.supp.2020.35.139.25368.
PMID: 33193954
8
An Endemic Region of Thiamine-Responsive Megaloblastic Anemia Caused by an SLC19A2 c.1223+1G>A Founder Mutation.
Gurzhikhanova M, Fomenko S, Chekanov N, et al.
International journal of molecular sciences 2026; (27(14)) doi:10.3390/ijms27146274.
PMID: 42511616
9
Thiamine-Responsive Megaloblastic Anemia-Related Diabetes: Long-Term Clinical Outcomes in 23 Pediatric Patients From the DPV and SWEET Registries.
Warncke K, Prinz N, Iotova V, et al.
Canadian journal of diabetes 2021; (45(6)):539-545 doi:10.1016/j.jcjd.2020.11.006.
PMID: 33388275
10
Early thiamine therapy in Rogers syndrome: Systematic review of hematologic, auditory and glycemic outcomes.
Upadhyay Z, Sudani S, Jain A
Bioinformation 2026; (22(1)):26-30 doi:10.6026/973206300220026.
PMID: 41960466
11
An Italian case series' description of thiamine responsive megaloblastic anemia syndrome: importance of early diagnosis and treatment.
Di Candia F, Di Iorio V, Tinto N, et al.
Italian journal of pediatrics 2023; (49(1)):158 doi:10.1186/s13052-023-01553-1.
PMID: 38037112
12
First 2 cases with thiamine-responsive megaloblastic anemia in the Czech Republic, a rare form of monogenic diabetes mellitus: a novel mutation in the thiamine transporter SLC19A2 gene-intron 1 mutation c.204+2T>G.
Pomahačová R, Zamboryová J, Sýkora J, et al.
Pediatric diabetes 2017; (18(8)):844-847 doi:10.1111/pedi.12479.
PMID: 28004468
13
LONG-TERM MULTIMODAL IMAGING OF OCULAR FINDINGS ASSOCIATED WITH THIAMINE-RESPONSIVE MEGALOBLASTIC ANEMIA.
Tsui E, Tauber J, Barbazetto I, Gelman SK
Retinal cases & brief reports 2020; (14(3)):247-250 doi:10.1097/ICB.0000000000000686.
PMID: 29210962
14
A Novel Mutation of SLC19A2 in a Chinese Zhuang Ethnic Family with Thiamine-Responsive Megaloblastic Anemia.
Xian X, Liao L, Shu W, et al.
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2018; (47(5)):1989-1997 doi:10.1159/000491467.
PMID: 29969779
15
Case Report: Genetic and Clinical Features of Maternal Uniparental Isodisomy-Induced Thiamine-Responsive Megaloblastic Anemia Syndrome.
Kang P, Zhang W, Wen J, et al.
Frontiers in pediatrics 2021; (9()):630329 doi:10.3389/fped.2021.630329.
PMID: 33816400
16
Leber congenital amaurosis as an initial manifestation in a Chinese patient with thiamine-responsive megaloblastic anemia syndrome.
Wu S, Yuan Z, Sun Z, et al.
American journal of medical genetics. Part A 2022; (188(3)):948-952 doi:10.1002/ajmg.a.62582.
PMID: 34821467

This page is for informational purposes only and does not constitute medical advice about high-dose thiamine treatment for TRMA. Your child's metabolic specialist and prescribing team should determine dosing, monitoring, and any insulin changes.